SLU-PP-332 – Comprehensive Research Overview (2026)

SLU-PP-332 is a synthetic small-molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ). It is researched as a potent exercise-mimetic that activates the transcriptional program of endurance exercise in skeletal muscle and other metabolic tissues. SLU-PP-332 is primarily studied for obesity, metabolic syndrome, sarcopenia, and conditions where exercise capacity is limited. It has no human clinical trials as of April 2026 but has generated significant preclinical interest.

→ View SLU-PP-332 (for laboratory research use only)

Mechanism of Action

  • Activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), which are master regulators of mitochondrial biogenesis and oxidative metabolism.
  • Upregulates genes involved in fatty acid oxidation, mitochondrial function, and slow-twitch muscle fiber development.
  • Mimics the transcriptional signature of endurance exercise training in skeletal muscle.
  • Reduces fat mass and improves metabolic flexibility without requiring physical activity.

Clinical Evidence and Research Findings

Preclinical studies in mice demonstrate significant improvements in exercise endurance, fat loss, and metabolic markers. SLU-PP-332-treated mice showed increased running capacity, reduced adiposity, and improved mitochondrial density in muscle. No human clinical trials have been published as of April 2026, but it is considered one of the most promising exercise-mimetic compounds in development.

→ Interested in researching SLU-PP-332? View Product Options

Benefits (Research & Clinical Observations)

  • Significant improvements in exercise endurance capacity
  • Fat loss and improved body composition
  • Enhanced mitochondrial biogenesis in skeletal muscle
  • Metabolic flexibility and insulin sensitivity improvements
  • Potential for sarcopenia and muscle wasting research

Typical Dosing Protocols (Preclinical)

  • Preclinical mouse studies: ~50–100 mg/kg orally
  • Human equivalent dosing not established; no approved clinical protocols

Safety Profile

Favorable preclinical safety profile with no significant organ toxicity reported at effective doses. Long-term safety and human data are not available.

Summary

SLU-PP-332 is a pan-ERR agonist that activates the endurance exercise transcriptional program, offering a compelling exercise-mimetic approach to metabolic disease and sarcopenia research. Its preclinical results are among the most impressive in the exercise-mimetic space. As with all compounds in this library, SLU-PP-332 is not an approved drug and should only be considered under qualified research supervision.

For Laboratory Research Use View SLU-PP-332 →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.